文献速递中医内科中药与中成药合理使用

扶正抗癌方调控非小细胞肺癌肿瘤微环境机制研究

Mechanism of Fuzheng Kang'ai Formula Regulating Tumor Microenvironment in Non-Small Cell Lung Cancer.
PubMed 文献 · Chin J Integr Med · 2021-09-21

本研究利用CIBERSORTx分析肿瘤微环境,结合TCMSP和TCGA-LUAD数据筛选差异表达基因,并通过Cox回归识别预后相关靶点,探讨扶正抗癌方对非小细胞肺癌肿瘤微环境的作用机制。结果显示CCNA2是扶正抗癌方的重要靶点(HR=1.41,95%CI:1.01-2.01,P<0.05),与肥大细胞状态相关,其下游基因BCL1L2、ACTL6A和ITGAV在A549细胞中经qRT-PCR验证。结论提示扶正抗癌方可能通过直接结合CCNA2并调控其下游基因及肿瘤微环境抑制肿瘤生长。

要点

  • CCNA2是扶正抗癌方调控LUAD肿瘤微环境的重要预后靶点。
  • CCNA2表达与肥大细胞活化正相关、与静息状态负相关。
  • BCL1L2、ACTL6A和ITGAV为CCNA2下游基因,已在A549细胞验证。

核心结论

  • 扶正抗癌方可能直接结合CCNA2,通过调控CCNA2下游基因及与非小细胞肺癌密切相关的肿瘤微环境抑制肿瘤生长。

研究设计与样本

  • 采用CIBERSORTx分析肿瘤微环境,TCMSP构建化合物-靶点网络,TCGA-LUAD数据识别肿瘤与癌旁组织差异表达基因。
  • 通过单因素和多因素Cox回归计算LUAD预后相关差异表达基因,并在A549、H1299和PC9细胞系中进行qRT-PCR生物学实验。

主要发现

  • 活化和静息肥大细胞与LUAD预后显著相关(P<0.05)。
  • CCNA2是扶正抗癌方的重要靶点(HR=1.41,95%CI:1.01-2.01,P<0.05),为预后靶点且与肥大细胞显著相关。
  • CCNA2与肥大细胞活化正相关,与肥大细胞静息状态负相关。
  • BCL1L2、ACTL6A和ITGAV为CCNA2下游基因,并在A549细胞中经qRT-PCR验证。

临床怎么用

  • CCNA2及其下游基因BCL1L2、ACTL6A、ITGAV可作为扶正抗癌方调控非小细胞肺癌肿瘤微环境的潜在分子标志。
  • 肥大细胞活化状态可能作为评估扶正抗癌方疗效的微环境相关指标。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: To study the mechanism of Chinese herbal medicine Fuzheng Kang'ai Formula (, FZKA) on tumor microenvironment (TME). METHODS: CIBERSORTx was used for analysis of TME. Traditional Chinese Medicine Systems Pharmacology and Analysis Platform was applied to identify compounds-targets network and the Cancer Genome Atlas (TCGA) was employed to identify the differential expression genes (DEGs) between tumor and paracancerous tissues in lung adenocarcinoma (LUAD) from TCGA-LUAD. Additionally, DEGs with prognosis in LUAD was calculated by univariable and multivariate Cox regression. The core targets of FZKA were analyzed in lung adenocarcinoma TME. Protein-protein interaction database was employed to predict down-stream of target. Quantitative reverse transcription polymerase chain reaction was employed for biological experiment in A549, H1299 and PC9 cell lines. RESULTS: The active and resting mast cells were significantly associated with prognosis of LUAD (P<0.05). Of the targets, CCNA2 as an important target of FZKA (hazard ratio=1.41, 95% confidential interval: 1.01-2.01, P<0.05) was a prognostic target and significantly associated with mast cells. CCNA2 was positively correlated with mast cell activation and negatively correlated with mast cell resting state. BCL1L2, ACTL6A and ITGAV were down-stream of CCNA2, which were validated by qRT-PCR in A549 cell. CONCLUSION: FZKA could directly bind to CCNA2 and inhibit tumor growth by regulating CCNA2 downstream genes and TME of NSCLC closely related to CCNA2.

来源:Chin J Integr Med,查看原文。版权归原作者所有。

引用

  1. Tian YL, Fu SB, Li B, et al. Mechanism of Fuzheng Kang'ai Formula Regulating Tumor Microenvironment in Non-Small Cell Lung Cancer. Chin J Integr Med. 2021. PMID: 34546538. doi:10.1007/s11655-021-3451-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。